Plain-English translation of NCT07003620 on ClinicalTrials.gov ↗ · Source last updated ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing paclitaxel and carboplatin combined with PD-1/PD-L1 immune checkpoint inhibitors — a new treatment approach for advanced cervical cancer. The study will give patients three rounds of this medication combination before they have surgery to remove the cancer. Researchers also want to understand why some patients respond better to the treatment than others by studying tumor samples.
Currently, standard treatment for advanced cervical cancer involves chemotherapy and radiation, but outcomes are not always good enough. This trial is testing whether adding an immune-boosting medication to chemotherapy can help more patients achieve better tumor shrinkage before surgery, potentially improving survival.
You likely qualify if…
You likely don't qualify if…
You would receive three cycles of the medication combination (chemotherapy plus immune therapy) given over several weeks. During this time, doctors will monitor you closely with scans and blood tests to see how your cancer is responding. After the medication treatment is complete, you would have surgery to remove the cancer and nearby lymph nodes. Following surgery, your doctor may recommend additional treatment based on what they find. Researchers will also collect tumor tissue samples to study how your cancer responds to the treatment.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China